Clearance rate of serum-free and total PSA following radical retropubic prostatectomy

Prostate

Volumn 29, Issue SUPPL. 7, 1996, Pages 35-39

  Partin, Alan W ^a,c   Piantadosi, Steven ^a   Subong, Eric N P ^a   Kelly, Cynthia A ^a   Hortopan, Steven ^a   Chan, Daniel W ^a   Wolfert, Robert L ^b   Rittenhouse, Harry G ^b   Carter, H Ballentine ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hybritech Incorporated   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

clearance; free PSA; prostate cancer; PSA; surgery; total PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; CLINICAL ARTICLE; COMPARTMENT MODEL; CONFERENCE PAPER; FOLLOW UP; HUMAN; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; ARTICLE; CANCER STAGING; HALF LIFE TIME; METABOLISM; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE PERIOD; PROSTATE TUMOR;

AGED; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0030340388     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(1996)7+<35::AID-PROS5>3.0.CO;2-I     Document Type: Conference Paper

References (16)

1. Partin AW, Oesterling JE: The clinical usefulness of prostate specific antigen: Update 1994. J Urol 152:1358-1368, 1994.
2. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, Brendler CB, Walsh PC: Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139:766-772, 1988.
3. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen based screening. JAMA 270: 948-954, 1993.
4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
5. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years. Urol Clin North Am 20:713-725, 1993.
6. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, Oesterling JE: Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era. Urology 45:729-744, 1995.
7. Haab F, Meulemans A, Dauge C, Delmas V, Boccon-Gibod L: Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy. Prostate 26:334-338, 1995.
8. Lilja H: Significance of different molecular forms of serum PSA: The free, non-complexed form of PSA versus that complexed to α-antichymotrypsin. Urol Clin North Am 20:681-686, 1993.
9. 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344:1594-1598, 1994.
10. Catalona WB, Smith DS, Wolfert RL, Wang J, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum PSA to improve specificity of prostate cancer screening. JAMA 274:1214-1220, 1995.
11. Luderer AA, Chen Y-T, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, Thiel R: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 146:187-194, 1995.
12. Partin AW, Carter HB: The use of prostate specific antigen free/total PSA in the diagnosis of localized prostate cancer. Urol Clin North Am in press, 1996.
13. Pontes JE, Jabalameli P, Montie J, Foemmel R, Howard PD, Boyett J: Prognostic implications of disappearance rate of biologic markers following radical prostatectomy. Urology 36:415-419, 1990.
14. Semjonow A, Oberpenning F, Surdel W, Weining C, Brandt B, Brandau W, Herlte L, Hamm M: PSA and radical prostatectomy: Variation after manipulation of the prostate and consecutive elimination half-life of free and total PSA. J Urol 155:697, 1996.
15. Richardson TD, Wojno KJ, Liang LW, Gicherio DA, England BG, Henricks WH, Schork A, Oesterling JE: Serum half life determination of free prostate specific antigen: J Urol 155:698, 1996.
16. Agha AH, Schechter E, Roy JB, Culkin DJ: Prostate specific antigen is metabolized in the liver. J Urol 155: 379, 1996.